BioSpace News Archive

Today Vibrent Health announced a collaboration with Virginia Commonwealth University to support its digital research capabilities to streamline how researchers across the university collect, manage, share and utilize data.

We are proud to share that the unaudited number of tests processed by the ScreenPro team for the month of March were over 30,000.

Sixty-nine-year-old Mark Eisen says he waited seven years for a surgery he hopes will change his life. Last week, he had the first total wrist replacement with KinematX™, a new implant co-designed by Scott W. Wolfe, MD, chief emeritus of the Hand and Upper Extremity Service at Hospital for Special Surgery.

SecondWave Systems, Inc., a pioneer in the emerging field of bio-ultrasonic medicine, has secured $4 million of additional funding from the Department of Defense (DOD), bringing the total non-dilutive investment to $7.4 million.

Today, Bayer announced that two of its top Pharmaceutical executives will take on new leadership roles within the division to advance its position in key therapeutic areas.

The Radiology Group, LLC, an onsite and teleradiology solutions healthcare company, today announced its continued expansion through the acquisition of Strategic Imaging Consultants, a North Carolina based radiology practice with services in South Carolina and Arizona.

The Coalition for the Advancement of Research and Innovation in Trauma announced the addition of The Wake Forest Institute for Regenerative Medicine to its group of organizations whose mission is to establish the government coordination and funding necessary to enable greater innovation in trauma, acute care, emergency and pre-hospital care.

The Restructuring Agreement has been approved by the Board of Directors for both organizations and is now subject to the approval of CVR Medical’s shareholders and the TSX Venture Exchange (the “TSXV”).

Formalization of the current relationship will allow PharmaDrug to expedite development timelines by leveraging SwRI’s existing Cepharanthine preclinical data sets and considerable manufacturing know-how.

The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).